Dr. Matthew Milowsky, MD

• Medical Oncology

• Urologic Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Weill Cornell Medical Center

  Fellowship Hospital

• New England Medical Center

  Residency Hospital

• New England Medical Center

  Internship Hospital

• State University Of New York Downstate Health Sciences University College Of Medicine

  Medical School

• Associations between Tumor Vascularity, Vascular Endothelial Growth Factor Expression and PET/MRI Radiomic Signatures in Primary Clear-Cell-Renal-Cell-Carcinoma: Proof-of-Concept Study, 2017-03-03

• Identification of a novel inflamed tumor microenvironment signature as a predictive biomarker of bacillus Calmette-Guerin immunotherapy in non-muscle invasive bladder cancer, 2021-06-11

• Roadmap for the Development of the University of North Carolina at Chapel Hill G enitourinary O nco L ogy D atabase - UNC GOLD, 2013-02-19

• Trends in Stage-Specific Incidence Rates for Urothelial Carcinoma of the Bladder in the United States: 1988 to 2006, 2013-10-10

• Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study, 2018-04-13

• Fibroblast Growth Factor Receptor 3 Alteration Status Is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma, 2020-08-01

• Gender disparities in chemotherapy use and survival in patients with advanced bladder cancer, 2016-05-25

• BODY COMPOSITION, PHYSICAL FUNCTION AND QUALITY OF LIFE IN HEALTHY MEN AND ACROSS DIFFERENT STAGES OF PROSTATE CANCER, 2021-01-25

• Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule, 2017-07-25

• Trimodality therapy with or without neoadjuvant chemotherapy for muscle invasive bladder cancer, 2021-03-16

• New and Emerging Therapies in the Management of Bladder Cancer [version 1; peer review: 2 approved], 2020-09-16

• Pre-post Evaluation of Collaborative Oncology Palliative Care for Patients with Stage IV Cancer, 2021-02-27

• Phase II study of lutetium-177 labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer, 2013-05-28

• Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer, 2022-11-04

• Cancer Associated Fibroblasts: An Understudied but Critical Component of the Tumor Microenvironment in Urothelial Cancer, 2023-06-01

• SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer, 2018-09-20

• Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma, 2017-08-15

• Impairment and Longitudinal Recovery of Older Adults Treated with Radical Cystectomy for Muscle-Invasive Bladder Cancer, 2020-07-27

• Micropapillary Bladder Cancer: Current Treatment Patterns and Review of the Literature, 2014-06-13

• Racial disparities in survival in advanced renal cell carcinoma in the targeted therapy era, 2016-06-24

• Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance, 2015-10-01

• Modeling Cost-Effectiveness of a Biomarker-Based Approach to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer, 2018-04-24

• Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings, 2015-06-27

• A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer, 2021-06-21

• A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer (SWOG S1314;NCT02177695), 2021-02-10

• Neoadjuvant Chemotherapy for Bladder Cancer Does Not Increase Risk of Perioperative Morbidity, 2014-03-14

• Metachronous Bilateral Testicular Leydig-Like Tumors Leading to the Diagnosis of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome), 2015-08-16

• The Association of Hospital Volume With Conditional 90-day Mortality After Cystectomy: An Analysis of the National Cancer Database, 2014-05-22

• Erratum to: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma, 2017-09-28